earnings
confidence high
sentiment neutral
materiality 0.65
Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M
Fulgent Genetics, Inc.
- Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.
- GAAP net loss $14.6M ($0.48 per share); non-GAAP net income $9.4M ($0.31 per share).
- Adjusted EBITDA income $0.4M; cash and marketable securities $815.4M.
- Reiterated FY2024 core revenue guidance of $280M; improved EPS guidance for 2024.